Compare Datadog Inc (DDOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Datadog Inc vs Novo Nordisk A/S — how do they compare? Datadog Inc trades at $248.96 (market cap $88.61B), while Novo Nordisk A/S trades at $46.07 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.3× Datadog Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Datadog Inc pays none. Which is the better fit depends on your goals.
| DDOG | NVO | |
|---|---|---|
Market Cap | $88.61B | $207.85B |
Sector | Technology | Health |
52-Week High | $288.15 | $63.98 |
52-Week Low | $102.62 | $35.29 |
Enterprise Value | $84.90B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Datadog (DDOG) trades at $260.78, up 11.48% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations with EPS of $0.65 versus $0.583 estimated. Revenue grew 36% year-over-year, and the company raised full-year 2026 guidance. Technical indicators show a bullish trend with support at $239 and resistance at $272, while high valuation multiples like a P/E of 493.56 signal premium pricing. Recent news highlights AI-driven growth but also insider selling and market sensitivity to guidance nuances.
The outlook remains positive due to robust revenue growth and AI adoption, but risks include elevated valuations and customer concentration. Analyst consensus is strongly bullish with an average price target of $288.55, though investors should monitor execution against high expectations and competitive pressures in the cloud monitoring space.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Datadog Inc
Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
